{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:16:44Z","timestamp":1791199004771,"version":"4.1.0"},"reference-count":14,"publisher":"Japanese Pharmacological Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1254\/jphs.13162fp","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T23:27:44Z","timestamp":1390433264000},"page":"201-207","source":"Crossref","is-referenced-by-count":28,"title":["Detection of Thalidomide Embryotoxicity by In Vitro Embryotoxicity Testing Based on Human iPS Cells"],"prefix":"10.1254","volume":"124","author":[{"given":"Nobuo","family":"Aikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kunisato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Takaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinya","family":"Ohgami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","unstructured":"1 Genschow E, Scholz G, Brown N, Oiersma A, Brady M, Clemann N, et al. Development of prediction models for three in vitro embryotoxicity tests in an ECVAM validation study. In vitr Mol Toxicol. 2000;13:51\u201366."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Newman CG. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol. 1986;13:555\u2013573.","DOI":"10.1016\/S0095-5108(18)30810-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Stirling DI. Thalidomide and its impact in dermatology. Semin Cutan Med Surg. 1998;17:231\u2013242.","DOI":"10.1016\/S1085-5629(98)80019-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Fratta LD, Sigg EB, Maiorana K. Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice. Toxicol Appl Pharmacol. 1965;7:268\u2013286.","DOI":"10.1016\/0041-008X(65)90095-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Schumacher H, Blake DA, Gurian JM, Gillette JR. A comparison of the teratogenic activity of thalidomide in rabbits and rats. J pharmacol Exp Ther. 1967;160:189\u2013200.","DOI":"10.1016\/S0022-3565(25)27910-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Asai Y, Tada M, Otsuji TG, Nakatsuji N. Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode. Curr Stem Cell Res Ther. 2010;5:227\u2013232.","DOI":"10.2174\/157488810791824502"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Honda M, Kiyokawa J, Tabo M, Inoue T. Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. J Pharmacol Sci. 2011;117:149\u2013159.","DOI":"10.1254\/jphs.11038FP"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kao J, Brown NA, Schmid B, Goulding EH, Fabro S. Teratogenicity of valproic acid: in vivo and in vitro investigations. Teratog Carcinog Mutagen. 1981;1:367\u2013382.","DOI":"10.1002\/tcm.1770010405"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Menegola E, Broccia ML, Nau H, Prati M, Ricolfi R, Giavini E. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. Teratog Carcinog Mutagen. 1996;16:97\u2013108.","DOI":"10.1002\/(SICI)1520-6866(1996)16:2<97::AID-TCM4>3.0.CO;2-A"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Colomina MT, Gomez M, Domingo JL, Corbella J. Lack of maternal and developmental toxicity in mice given high doses of aluminium hydroxide and ascorbic acid during gestation. Pharmacol Toxicol. 1994;74:236\u2013239.","DOI":"10.1111\/j.1600-0773.1994.tb01104.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Kunisato A, Wakatsuki M, Shinba H, Ota T, Ishida I, Nagao K. Direct generation of induced pluripotent stem cells from human nonmobilized blood. Stem Cells Dev. 2011;20:159\u2013168.","DOI":"10.1089\/scd.2010.0063"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Scholz G, Genscow E, Pohl I, Bremer S, Paparella M, Raabe H, et al. Prevalidation of the embryonic stem cell test (EST)\u2015A new in vitro embryotoxicity test. Toxicol In Vitro. 1999;13:675\u2013681.","DOI":"10.1016\/S0887-2333(99)00046-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Seiler AE, Spielman H. The validated embryonic stem cell test to predict embryotoxicity in vitro. Nat Protoc. 2011;6:961\u2013978.","DOI":"10.1038\/nprot.2011.348"},{"key":"14","unstructured":"14 Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1245\u20131350."}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/124\/2\/124_13162FP\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:47:19Z","timestamp":1746118039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/124\/2\/124_13162FP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.13162fp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}